Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. It is used to treat and prevent deep vein thrombosis and pulmonary embolism (collectively known as venous thromboembolism) and is also used as part of the treatment of myocardial infarction and unstable angina. Heparin is used on the inside surfaces of various devices such as test tubes and kidney dialysis machines. Heparin is the foremost clinical anticoagulant with more than 500 million doses consumed globally each year. Heparin and related molecules exhibit a large number of newly discovered biological activities with optimum therapeutic potential. Advantages of heparin such as immediate onset of action, short half-life, simple laboratory monitoring, ability to be reversed (protamine), and low cost have led to its use worldwide. The major clinical applications of heparin include prevention of blood clotting during dialysis, unwanted blood clotting during open-heart surgery, and treatment of deep vein thrombosis and pulmonary embolism.
The global heparin anticoagulant market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global heparin anticoagulant market segmentation is based on products (unfractionated heparin, low molecular weight heparin, ultra-low molecular weight heparin), end users (blood and stem cell banks, hospitals, others).
The global heparin anticoagulant market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global heparin anticoagulant market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global heparin anticoagulant market and included in this report are Aspen Holdings, Baxter International, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, LEO Pharma A/S, Mylan N.V., Pfizer, Inc., Sanofi S.A., Syntex S.A., and Teva Pharmaceutical Industries Ltd.